Pulse Biosciences, Inc - PLSE STOCK NEWS

Pulse Biosciences (Nasdaq: PLSE) has announced an extension for its current rights offering to May 26, 2022, allowing shareholders more time to exercise their rights. The Alternate Price for shares will be based on the volume-weighted average price over five trading days prior to May 23, 2022. This change aims to accommodate reports that some brokers set earlier cut-off dates. The subscription price remains at the lesser of $3.72 or the calculated average price, with previously issued terms still in effect. The rights offering is registered with the SEC.

Pulse Biosciences, Inc. (Nasdaq: PLSE) reported Q1 2022 revenue of $444 thousand with system revenue of $367 thousand and cycle units revenue of $77 thousand. The company transitioned 10 Controlled Launch Program participants to commercial use, leading to a total of 39 commercial conversions by quarter-end. Despite a decrease in overall utilization, new leadership has been appointed to enhance strategies. However, GAAP net loss was ($17.3 million), an improvement from ($18.6 million) the previous year, while cash reserves dropped to $12.7 million.

Pulse Biosciences, Inc. (Nasdaq: PLSE) has initiated a rights offering to raise up to $15,000,000. Existing shareholders as of April 25, 2022 will receive non-transferable subscription rights to purchase Units, each comprising one share of Common Stock and a warrant. The initial price is set at $3.72 per Unit, but may adjust based on market conditions. The offering expires on May 23, 2022. This move is part of the company’s shelf registration statement effective since August 21, 2020.

Pulse Biosciences (NASDAQ: PLSE) will announce its financial results for Q1 2022 on May 11, 2022, after market close. A conference call will follow at 1:30 PM PT. Investors can join by dialing 1-877-704-4453 (domestic) or 1-201-389-0920 (international), or via a live webcast at investors.pulsebiosciences.com. The company is focused on innovative bioelectric medicine, leveraging its CellFX® System powered by Nano-Pulse Stimulation™ technology to enhance dermatologic treatments.

Pulse Biosciences (Nasdaq: PLSE) announced significant findings at the ASLMS Annual Meeting held from April 27-30, 2022, in San Diego, California. An oral presentation revealed that 12-month data for the treatment of Sebaceous Hyperplasia shows a 73% success rate in lesion clearance with good cosmetic results. A poster presentation discussed a successful case of HPV-related dermatosis treated with Nano-Pulse Stimulation (NPS). The findings highlight the clinical efficacy and safety of the CellFX® System for challenging dermatological conditions.

Pulse Biosciences, Inc. (PLSE) has announced a rights offering aimed at raising up to $15,000,000. Available to stockholders of record as of April 25, 2022, the offering will commence around May 4, 2022. Shareholders can purchase units consisting of one share of common stock and a warrant at a price based on the lesser of $3.72 or the volume-weighted average price prior to expiration on May 23, 2022. The rights offering, set to be registered with the SEC, is a strategic move to enhance liquidity and support growth initiatives.

Pulse Biosciences (Nasdaq: PLSE) announced its financial results for Q4 and full year 2021, reporting Q4 revenue of $844k and total annual revenue of $1.4 million. The company implemented leadership changes and initiated expense reduction programs to lower costs by 20%. Gross loss for Q4 was $0.4 million, with operating expenses increasing to $15 million. Full year GAAP net loss reached $63.7 million, an increase from 2020. The firm plans to enhance clinic utilization and expand the CellFX System's applications in dermatology.

Pulse Biosciences, Inc. (PLSE) will release its financial results for Q4 and full year 2021 after market close on March 31, 2022. A conference call hosted by management will follow at 1:30 PM PT. The company is known for its innovative CellFX® System using Nano-Pulse Stimulation™ technology to treat dermatologic conditions. This system aims to offer non-thermal solutions that can improve patient outcomes. Investors can access the earnings call via dial-in or webcast.

Pulse Biosciences (NASDAQ: PLSE) has appointed Kevin Danahy as its new Chief Commercial Officer (CCO). Danahy brings over 20 years of experience in medical technology, having previously driven revenue growth at Solmetex and held significant roles at Zimmer Biomet and Intuitive Surgical. His expertise is expected to enhance market penetration for the CellFX® System, which utilizes proprietary Nano-Pulse Stimulation technology to improve dermatologic outcomes. As part of his appointment, Danahy received 300,000 stock options, subject to performance-based criteria.